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Objective. To investigate the genetic background influencing the development of cardiovascular (CV) disease in 
patients with rheumatoid arthritis (RA).
Methods. We performed a genome- wide association study (GWAS) in which, after quality control and im-
putation, a total of 6,308,944 polymorphisms across the whole genome were analyzed in 2,989 RA patients 
of European origin. Data on subclinical atherosclerosis, obtained through assessment of carotid intima- media 
thickness (CIMT) and presence/absence of carotid plaques by carotid ultrasonography, were available for 1,355 
individuals.
Results. A genetic variant of the RARB gene (rs116199914) was associated with CIMT values at the genome- wide 
level of significance (minor allele [G] β coefficient 0.142, P = 1.86 × 10−8). Interestingly, rs116199914 overlapped with 
regulatory elements in tissues related to CV pathophysiology and immune cells. In addition, biologic pathway enrich-
ment and predictive protein–protein relationship analyses, including suggestive GWAS signals of potential relevance, 
revealed a functional enrichment of the collagen biosynthesis network related to the presence/absence of carotid 
plaques (Gene Ontology no. 0032964; false discovery rate–adjusted P = 4.01 × 10−3). Furthermore, our data suggest 
potential influences of the previously described candidate CV risk loci NFKB1, MSRA, and ZC3HC1 (P = 8.12 × 10−4, 
P = 5.94 × 10−4, and P = 2.46 × 10−4, respectively).
Conclusion. The present findings strongly suggest that genetic variation within RARB contributes to the develop-
ment of subclinical atherosclerosis in patients with RA.
INTRODUCTION
Cardiovascular (CV) disease is the most common cause of 
morbidity and mortality in patients with rheumatoid arthritis (RA) 
(1–3). In RA patients, CV disease may develop as a result of an 
accelerated atherosclerotic process (4). Surrogate markers for sub-
clinical atherosclerosis, i.e., increased carotid intima- media thick-
ness (CIMT) and presence of carotid plaques (5,6), are excellent 
Supported in part by the European Union FEDER fund and the Instituto 
de Salud Carlos III (ISCIII) (Fondo de Investigación Sanitaria grants PI06/0024, 
PS09/00748, PI12/00060, PI15/00525, and CP16/00033), the ISCIII RETICS 
programs (RD12/0009 and RD16/0012), the European IMI BTCure Program. 
Dr. López-Mejías is recipient of the Miguel Servet type I Program Fellowship 
from the ISCIII and the European Social Fund (ESF) (grant CP16/00033). Dr. 
Carmona’s work was supported by the Spanish Ministry of Economy and 
Competitiveness (Ramón y Cajal Program grant RYC-2014-16458). Dr. Genre 
is recipient of a Sara Borrell postdoctoral fellowship from the ISCIII and ESF 
(grant CD15/00095). Dr. Remuzgo-Martínez’ work was supported by the 
ISCIII and European Regional Development Fund (ERDF) (RETICS Program 
RD16/0012/0009). Ms Pulito-Cueto’s work was supported by a predoctoral 
grant from the Instituto de Investigación Sanitaria Valdecilla (PREVAL 18/01). 
Ms Mijares’ work was supported by the Miguel Servet type I Program from 
the ISCIII and ESF (grant CP16/00033). Dr. Gualillo is staff personnel of Xunta 
de Galicia (Servizo Galego de Saude [SERGAS]) through a research-staff 
stabilization contract (ISCIII/SERGAS) and his work is funded by ISCIII and 
FEDER (grants RD16/0012/0014 [RIER] and PI17/00409). He is beneficiary of 
project funds from the Research Executive Agency (REA) of the European 
Union in the framework of MSCA-RISE Action of the H2020 Programme, 
project 734899—Olive-Net.
1Raquel López-Mejías, PhD, Fernanda Genre, PhD, Sara Remuzgo-
Martínez, PhD, Alfonso Corrales, MD, PhD, Verónica Pulito-Cueto, BSc, Ricardo 
Blanco, MD, PhD, Verónica Mijares, BSc, Leticia Lera-Gómez, BSc: Instituto de 
LÓPEZ-­MEJÍAS­ET­AL­352       |
predictors of future CV events. Traditional CV risk factors and 
chronic inflammation do not fully explain the increased CV predis-
position observed in patients with RA, accounting for only ~70% 
of the population- attributable risk for CV disease outcomes (7). 
Cumulative knowledge clearly suggests that genetic factors may 
play a relevant role in this phenomenon (8), but the specific genetic 
component of CV disease in RA remains elusive.
Genome- wide association studies (GWAS) constitute a 
hypothesis- free approach in which millions of common genetic 
variations across the whole genome are interrogated (9). This 
strategy has been of great help in elucidating relevant inroads into 
the genetics of several complex human diseases (10). The use of 
this technology has substantially increased the number of estab-
lished RA susceptibility loci from 3 to >100 during the last decade 
(11). Nevertheless, there are currently no available GWAS data 
specifically focused on CV disease in patients with RA.
Taking into account all of these considerations, we undertook 
the first GWAS on the development of CV disease in RA. This 
multicenter study included a large number of patients with RA, in 
whom the presence/absence of CV events and subclinical ath-
erosclerosis were evaluated.
PATIENTS AND METHODS
Study population. A total of 3,433 unrelated Spanish 
patients of European ancestry, all of whom had RA accord-
ing to the 2010 American College of Rheumatology/Euro-
pean League Against Rheumatism classification criteria (12), 
were enrolled in the study. Centers involved in patient recruit-
ment included Hospital Universitario Lucus Augusti, Hospital 
Universitario Marqués de Valdecilla, Hospital Universitario de 
Basurto, Hospital Universitario Central de Asturias, Hospital 
Clínico Universitario de Santiago, Hospital Universitario de 
Bellvitge, Hospital Universitario San Cecilio, Hospital Universi-
tario Reina Sofía, Hospital Universitario de Canarias, Hospital 
Universitario Doctor Peset, Hospital General Universitario de 
Ciudad Real, Hospital Clínico San Carlos, Hospital Universitario 
La Paz, Hospital Universitario de la Princesa, Hospital General 
Universitario Gregorio Marañón, and Hospital Universitario 12 
de Octubre. Before being included in the study, all patients 
provided written informed consent according to the Declara-
tion of Helsinki. The procedures followed were in accordance 
with the standards and requirements of the human experimen-
tation ethics committees at all participating centers.
Genotyping and quality control. Genomic DNA was 
extracted from peripheral blood using standard procedures. 
Genotyping was conducted at the Human Genotyping Unit of the 
National Genotyping Center in Spain, using the GWAS platform 
Infinium HumanCore BeadChip in an iScan system, according to 
the protocol recommended by the manufacturer (Illumina). Single- 
nucleotide polymorphisms (SNPs) with a cluster separation of 
<0.4 were removed after the calling.
Raw data were subjected to stringent quality control filters 
using the software Plink (version 1.07) (13). Polymorphisms with 
call rates of <0.98 and minor allele frequencies of <0.01, as well as 
those that deviated from Hardy- Weinberg equilibrium (P < 0.001), 
were filtered out. Similarly, samples with <95% successfully called 
polymorphisms, and 1 subject per pair of first- degree relatives 
(identity by descent >0.4), were removed. Sex chromosomes 
were also excluded from the analysis.
To ensure reliability of the results, the associated SNP 
described below was re- genotyped using a predesigned TaqMan 
5′ SNP genotyping assay (C_154503570_10) in a 7900HT Fast 
Real- Time PCR System (Applied Biosystems), and the TaqMan 
types were compared with the corresponding imputed data.
Imputation methods. After application of the quality 
control filters, whole- genome SNP genotype imputation in auto-
somal chromosomes was carried out in the Michigan Imputation 
Server (MIS) (14), using ShapeIT16 software (version v2.r790) 
for haplotype reconstruction and the updated Haplotype Refer-
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ence Consortium data (version r1.1) as a reference panel, which 
combine sequencing data from a total of 32,470 individuals from 
multiple studies (including the 1000 Genomes Project) (15). The 
quality control filters mentioned above were also applied to the 
imputed data using Plink. In addition, singletons (r2 ≤ 0.2) were 
excluded. Finally, possible population substratification was con-
trolled by principal components (PC) analysis using Plink and 
gcta64 and R- base software under GNU Public license v2. The 
first 10 PCs for each individual were calculated and plotted to 
identify outliers, and those deviating from the cluster centroid by 
>4 SD were excluded.
After quality control, 6,308,944 SNPs and 2,989 RA patients 
remained for analysis in the final data set. Data on demographic, 
RA clinical, and CV disease–related characteristics are shown in 
Table 1. Information related to CV events was obtained from the 
medical records of each patient, with traditional CV risk factors and 
CV events defined as previously described (3,6). Briefly, individuals 
were considered to have ischemic heart disease (IHD) if any of the 
following criteria were satisfied: a recorded diagnosis of ischemic 
cardiopathy due to an acute coronary syndrome (acute myocardial 
infarction or unstable angina), abnormal Q waves seen on electro-
cardiography, and/or >50% stenosis of at least 1 coronary vessel 
seen on coronary images. A patient was considered to have heart 
failure based on the Framingham criteria. Cerebrovascular accident 
was recorded if patients had a stroke and/or transient ischemic 
attacks (TIAs). Strokes were classified according to their clinical 
features and were confirmed by computed tomography and/or 
magnetic resonance imaging. TIAs were diagnosed if the symp-
toms were self- limited in <24 hours, without residual neurologic 
damage. Finally, peripheral arterial disease was considered to be 
present if confirmed by Doppler imaging and arteriography (3,6).
Subclinical atherosclerosis examination. Informa-
tion on subclinical atherosclerosis was available for 1,355 RA 
patients from the filtered data sets. Subclinical atherosclerosis 
examination was assessed with a carotid ultrasound tech-
nique (evaluation of CIMT and presence/absence of carotid 
plaques). At the hospitals in Santander, Bilbao, Granada, 
Córdoba, Tenerife, Valencia, Ciudad Real, and Madrid, the 
ultrasound examination was performed using a commercial 
scanner (16,17). Patients from Lugo were assessed by high- 
resolution B- mode ultrasound (18). CIMT was measured at the 
far wall of the right and left common carotid arteries over the 
proximal 15- mm–long segment. CIMT was determined as the 
average of 3 measurements in each common carotid artery. 
Consistency of results between these 2 ultrasound methods 
was previously reported (19), supporting the fact that the use 
of 2 different instruments to collect CIMT data did not influence 
the results derived from this analysis. In addition, these studies 
were performed by experts with high intra- and interobserver 
reliability, who have collaborated closely in the assessment of 
subclinical atherosclerosis in RA. Criteria for determining the 
presence of plaque in the accessible extracranial carotid tree 
were defined as described by Touboul et al (20).
Statistical analysis. Estimations for statistical power 
were obtained with CaTS Power Calculator for Genetic Stud-
ies software, which implements the methods described by 
Skol et  al (21) (Supplementary Tables 1–4, on the Arthritis 
& Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.40734/abstract). All statistical analyses were 
conducted with Plink. First, we compared the genotype fre-
quencies of all SNPs according to a continuous CV disease 
outcome variable (CIMT values) by linear regression assum-
ing an additive model. The first 10 PCs, age at the time of 
the carotid ultrasound examination, and sex were included 
in the model as covariates. Subsequently, we compared the 
genotype frequencies of all SNPs according to binary CV 
disease outcome variables (presence/absence of CV events, 
IHD, and carotid plaques) by logistic regression on the 
best- guess genotypes assuming an additive model. The first 
Table 1. Demographic, clinical, and CV disease–related character-
istics of the 2,989 RA patients whose samples were included in the 
filtered data set* 
Demographic and RA characteristics
Age at the time of disease onset, 
mean ± SD years
49.8 ± 14.9
Follow- up time, mean ± SD years 11.7 ± 9.1
Women, % 74.7
RF positive† 1,585/2,432 (65.2)
ACPA positive 1,365/2,286 (59.7)
Erosions 1,125/2,148 (52.4)
Extraarticular manifestations‡ 575/1,994 (28.8)
Traditional CV risk factors 
Hypertension 1,018/2,585 (39.4)




CV events 467/2,989 (15.6)
Ischemic heart disease 224/2,989 (7.5)
Heart failure 146/2,989 (4.9)
Cerebrovascular accident 125/2,989 (4.2)
Peripheral artery disease 60/2,989 (2.0)
* Except where indicated otherwise, values are the number of pa-
tients/number assessed (%). CV = cardiovascular; RA = rheumatoid 
arthritis; RF = rheumatoid factor; ACPA = anti–citrullinated protein 
antibody. 
† At least 2 determinations at different times were required for 
analysis of this result. 
‡ Patients were considered to have extraarticular manifestations if 
they experienced at least 1 of the following: nodular disease, Fel-
ty’s syndrome, pulmonary fibrosis, rheumatoid vasculitis, or sec-
ondary Sjögren’s syndrome (3). 
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10 PCs, age at the time of RA diagnosis, and sex were included 
as covariates for the presence/absence of CV events and IHD 
analyses, and the first 10 PCs, age at the time of carotid ultra-
sound examination, and sex were included as covariates for 
the presence/absence of carotid plaque analysis. Finally, P val-
ues, beta coefficients, standard errors, odds ratios, and 95% 
confidence intervals were calculated. The statistical threshold 
was set at the genome- wide level of significance (P < 5 × 10−8).
Performance of functional annotations of the asso-
ciated variants. In a further step, we evaluated the putative 
functional implications of the identified CV risk signals by inte-
grating our data with functional annotation data available in public 
databases, using different bioinformatics approaches. For this pur-
pose, we first identified all of the potential polymorphisms in high 
linkage disequilibrium (LD; r2 > 0.8) of the associated signals of our 
GWAS, using the European populations from the 1000 Genomes 
Project and Plink. All of those potential polymorphism taggers 
would be considered equally as candidates for prioritizing cau-
sality or hypothesizing possible molecular causes of the observed 
associations in the subsequent bioinformatic approaches. Then, 
the online tools RegulomeDB (22), HaploReg (version 4.1) (23), 
and Capture HiC Plotter (CHi-CP) (24) were used to evaluate the 
possible regulatory effect of the associated signals and their pos-
sible implications in the clinical phenotypes analyzed.
Candidate genomic regions and pathway enrich-
ment analysis. Finally, we assessed the statistical significance 
in our GWAS of previously described CV risk–associated genomic 
regions (±100 kbp 3′ and 5′ of the reported gene) through can-
didate gene studies (8) and a recently published meta- analysis of 
ImmunoChip data (25). Regarding the HLA region, a more com-
prehensive analysis was conducted. We extracted the extended 
HLA region (29,000,000–34,000,000 bp in chromosome 6) and 
imputed SNPs, classic HLA alleles at 2- and 4- digits, and poly-
morphic amino acid positions, as previously described (26–28).
Additionally, a biologic pathway enrichment analysis involving 
genes that showed suggestive P values in our study (P < 1 × 10−4) 
was performed by using the tool for that purpose from the Gene 
Ontology (GO) reference genome project (29,30), powered by the 
Protein Analysis Through Evolutionary Relationships Classification 
System (31). Moreover, we conducted a predictive protein–protein 
interaction analysis among these same markers, using the Search 
Tool for the Retrieval of Interacting Genes/Proteins database (32). 
P values less than 0.05 after correction for multiple testing were 
considered significant.
RESULTS
Testing for association with CV disease outcomes. 
Figure  1 and Supplementary Figure 1 (available on the Arthri-
tis & Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.40734/abstract) summarize the overall results 
obtained for each CV disease outcome analysis performed. Inter-
estingly, a statistically significant signal at the genome- wide level 
of significance was associated with CIMT values (Figure 1). This 
signal corresponded with the genetic variant rs116199914, which 
maps to the 3′- untranslated region (3′- UTR) of the retinoic acid 
receptor β gene (RARB) (Table 2). The minor allele (G) of this SNP 
was significantly related to increased CIMT values (β = 0.142, 
Figure 1. Manhattan plot representation of the analysis of carotid intima- media thickness values as the cardiovascular disease outcome. 
The −log10 P values are plotted against their physical chromosomal position. The red line represents the genome- wide level of significance 
(P < 5 × 10−8).
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P = 1.86 × 10−8) (Table 2). To rule out the possibility that bias due 
to incorrect genotyping or imputation could have affected these 
results, we obtained direct genotypes using TaqMan probes 
for rs116199914. The overall concordance reached after com-
paring TaqMan types with the corresponding imputed data was 
99.94%. Based on previous studies that demonstrated associ-
ation between anti–citrullinated protein antibody (ACPA) positivity 
and CV disease in RA (33,34), we evaluated the potential associ-
ation between the genetic variant rs116199914 and ACPA status. 
However, no statistically significant results were observed (data 
not shown). Several suggestive associations with CIMT values 
were also detected, although none of them reached the genome- 
wide level of statistical significance (Figure  1). Among them, 
intronic variants of both RARB and the positive regulatory domain 
zinc- finger protein 10 gene (PRDM10), as well as a disequilibrium 
block of intergenic polymorphisms at chromosome 12, had the 
most suggestive P values.
Likewise, several trends of association were observed 
when the presence/absence of CV events, IHD, and carotid 
plaques were analyzed (Table 2 and Supplementary Figure 1, 
http://onlinelibrary.wiley.com/doi/10.1002/art.40734/abstract). 
Regarding the presence/absence of CV events, 2 intergenic 
variants in high LD at chromosome 1 exhibited the lowest P 
values. According to the presence/absence of IHD, an intronic 
variant of the kinesin family member 26B gene (KIF26B) and 
2 disequilibrium blocks of polymorphisms at chromosomes 1 
and 7 represented the strongest signals. Similarly, an intronic 
variant of the formin 2 gene (FMN2) and intergenic polymor-
phisms located at chromosomes 4, 9, and 17 exhibited the 
lowest P values regarding the presence/absence of carotid 
plaques.
Similar results were obtained when the analyses were 
also performed with traditional CV risk factors (smoking, dia-
betes mellitus, hypertension, obesity, and dyslipidemia) as 
covariates. In this regard, a statistically significant signal at 
the genome- wide level of significance that corresponded to 
RARB rs116199914 was associated with CIMT values (minor 
allele β = 0.137, P = 4.35 × 10−8). In addition, trends of asso-
ciation were again observed when the presence/absence of 
CV events, IHD, and carotid plaques were analyzed (data not 
shown).
Functional annotations of the associated variants. 
We evaluated the possible functional implications of the associ-
ated genetic variant rs116199914 by integrating our data with 
data from public databases. First, we searched for proxies (r2 > 
0.8) of rs116199914 in the 5 populations of European origin in the 
1000 Genomes Project (Iberian population in Spain, Utah residents 











β [SE] or 
OR (95% CI)
CIMT values
3 25.638.355 rs116199914 RARB (3′- UTR) G<A G 0.012 1.86 × 10−8† 0.142 [0.025]
3 25.622.694 rs77388418 RARB (intronic) C<T C 0.014 2.07 × 10−7 0.124 [0.024]
12 63.337.536 rs1695024 8 kb 3′ of Y_RNA A<G A 0.230 2.64 × 10−7 0.031 [0.006]
11 129.852.180 rs111703287 PRDM10 (intronic) T<C T 0.014 3.90 × 10−7 0.119 [0.023]
CV events
1 166.485.891 rs6684311 27 kb 5′ of RP11- 
276E17.2
G<C G 0.189 2.85 × 10−7 1.68 (1.38–2.05)
IHD
1 245.338.976 rs112844193 KIF26B (intronic) T<C T 0.054 1.35 × 10−7 2.67 (1.85–3.85)
7 120.966.790 rs3779381 WNT16 (intronic) G<A G 0.283 2.09 × 10−7 1.77 (1.23–2.19)
1 156.057.417 rs112941217 LMNA (intronic) C<T C 0.030 4.67 × 10−7 4.81 (2.61–8.87)
Carotid 
plaques
17 15.008.430 rs8066891 123 bp 3′ of RP11- 
924A14.1
G<A G 0.171 4.47 × 10−6 0.58 (0.46–0.73)
9 29.148.449 rs12683261 259 kb 5′ of 
MIR873
A<G A 0.031 4.57 × 10−6 0.25 (0.14–0.45)
1 240.599.906 rs9727451 FMN2 (intronic) A<G A 0.087 4.69 × 10−6 2.13 (1.54–2.95)
4 166.579.647 rs2611206 26 kb 5′ of RP11- 
 340B18.1
A<G A 0.126 4.84 × 10−6 0.53 (0.41–0.69)
* CV = cardiovascular; Chr. = chromosome; SNP = single- nucleotide polymorphism; MAF = minor allele frequency; OR = odds ratio; 95% CI = 
95% confidence interval; CIMT = carotid intima- media thickness; 3′- UTR = 3′- untranslated region; IHD = ischemic heart disease. 
† Statistically significant at the genome- wide level of significance. 
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of North and Western European ancestry, British in England and 
Scotland, Toscani in Italy, and Finnish in Finland). Since no proxies 
were identified, we functionally annotated just the rs116199914 
polymorphism. As this SNP is located in the 3′- UTR of the RARB 
gene, we used bioinformatic tools aimed at exploring annotations 
of the noncoding genome with putative regulatory effects on gene 
expression (including effect on regulatory motifs, chromatin state, 
and protein binding, as well as expression from expression quanti-
tative trait locus studies) in GEO, ENCODE, Roadmap Epigenom-
ics, and promoter CHi- C data sets, and published literature.
Interestingly, RegulomeDB results suggested that rs116199914 
may represent a DNA element with relevant regulatory effects 
(score 6). Additional functional implications were suggested with 
both HaploReg version 4.1. and CHi- C. In particular, overlapping 
with histone marks in tissues related to CV pathophysiology and 
cells of the immune system was observed (Figure 2). Specifically, 
rs116199914 was described to overlap with the enhancer histone 
mark H3K4me1 and the promoter histone mark H3K9ac in fetal 
heart, and with histone marks enriched at promoters and enhanc-
ers in immune cells (23). Furthermore, as derived from the CHi- C 
data sets, rs116199914 was reported to interact with, among 
others, NF- κB inhibitor–interacting Ras- like 1 gene (NKIRAS1) in 
total CD4 Mycosis fungoides cells and total CD8 cells (35) (Sup-
plementary Figure 2, on the Arthritis & Rheumatology web site 
at http://onlinelibrary.wiley.com/doi/10.1002/art.40734/abstract). 
In addition, rs116199914 was described to affect the sequence- 
specific binding for NFAT (23).
Candidate genes and pathway analysis. We also 
determined the statistical significance, in our GWAS, of previously 
described CV risk genes by candidate studies (8) and a recently 
published meta- analysis of ImmunoChip data (25). P values of 
<0.05 were observed across most of the evaluated loci (Sup-
plementary Table 5, http://onlinelibrary.wiley.com/doi/10.1002/
art.40734/abstract). Among them, the lowest P values were 
detected for associations of the NFKB1 and methionine sulfoxide 
reductase A gene (MSRA) regions with the presence of CV events 
(P = 8.12 × 10−4 and P = 5.94 × 10−4, respectively), as well as the 
zinc- finger C3HC- type containing 1 gene (ZC3HC1) region with 
CIMT values (P = 2.46 × 10−4). The association between NFKB1 
and CV events remained statistically significant after correction 
for multiple testing (rs227361, false discovery rate–adjusted P = 
4.50 × 10−2). Regarding the HLA system, no statistically significant 
results were observed across this genomic region (Supplementary 
Figure 3, http://onlinelibrary.wiley.com/doi/10.1002/art.40734/
abstract).
In addition, analysis of possible biologic pathway enrich-
ments and predictive protein–protein relationships was performed 
for the gene products of loci that showed P values of potential 
relevance in our study (P < 1 × 10−4). In this regard, the molec-
ular network of the selected proteins related to the presence/
absence of carotid plaques had significantly more interactions 
than expected (number of nodes 51, number of edges 8, aver-
age node degree 0.314, clustering coefficient 0.235; expected 
number of edges 3, protein–protein interaction enrichment P = 
1.68 × 10−2) (Figure 3). In accordance with the functional enrich-
ments of the network, the most significantly associated GO term 
corresponded to “collagen biosynthetic process” (GO number 
0032964) (false discovery rate–adjusted P = 4.01 × 10−3). No 
statistically significant results were obtained when these analyses 
were performed according to CIMT values, presence/absence of 
CV events, or IHD.
DISCUSSION
During the last decade, the genetic basis of the increased 
predisposition to CV disease observed in RA patients has been 
comprehensively investigated using a candidate gene strategy 
(8). However, not until the present study have GWAS data been 
 generated and analyzed. Therefore, the results presented here 
may represent a turning point for better understanding of the path-
ogenic mechanisms underlying this severe complication of RA.
A genetic marker of the RARB gene (rs116199914) was 
associated, at the genome- wide level of significance, with 
Figure 2. Regulatory chromatin annotations of RARB rs116199914 in tissues related to cardiovascular pathology and cells of the immune 
system, according to ENCODE data. The chromatin 15- state model was developed using 5 marks and 127 epigenomes from the Roadmap 
Epigenomics Project. G- CSF = granulocyte colony- stimulating factor; PMA- I = phorbol myristate acetate/ionomycin.
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subclinical atherosclerosis, assessed by CIMT. Interestingly, this 
signal overlaps with promoter and enhancer histone marks in 
fetal heart and immune cells. In addition, rs116199914 has been 
described to interact with the gene NKIRAS1. These data are 
striking, as NKIRAS1 encodes a crucial protein for the inhibition 
of NF- κB (36,37), which is one of the most relevant molecules 
involved in inflammation processes (38) and is considered to be 
a key regulator of several atherosclerosis genes (39). A previous 
candidate gene study demonstrated the influence of a promoter 
genetic variant in the NF- κB coding gene (NFKB1) on the risk of 
developing CV events among patients with RA (39). Additionally, 
the use of drugs that block cytokines of the NF- κB signaling path-
way has been described as a promising therapeutic strategy to 
attenuate the heightened CV risk in patients with RA (40,41) and 
to provide a beneficial effect on surrogate CV disease markers in 
those patients (42,43).
In addition, the associated variant identified in our study 
was shown to affect sequence- specific binding of NFAT, which 
regulates inducible gene transcription during the immune 
response (44–46). Originally, NFAT was described as being 
mainly expressed in activated T cells (46) and other immune 
cells (45). Currently, its regulatory roles in blood vessels and 
heart tissue are well established (47–49). Furthermore, a role 
of this molecule in angiogenic processes has been confirmed 
(48). Consistent with this, cumulative knowledge clearly demon-
strates that the chronic inflammation observed in patients with 
RA, critical for the development of atherosclerosis, is often 
accompanied by imbalanced angiogenesis (50). In accordance 
with that, increased serum levels of the angiogenic molecule 
angiopoietin 2 have been found to correlate with the develop-
ment of CV events in patients with RA (50).
Our results suggest a functional impact of the genetic variant 
RARB rs116199914. In this regard, it could be speculated that the 
interaction between this polymorphism and NKIRAS1 modulates 
the expression of the latter, affecting the inhibition of NF- κB. This 
may trigger the regulation of genes encoding proinflammatory 
cytokines, adhesion molecules, chemokines, and inducible nitric 
oxide synthase, thus contributing to endothelial damage and sub-
sequently to CV disease. Similarly, since RARB rs116199914 has 
been described to affect the sequence- specific binding of NFAT as 
noted above, it may be reasonable to consider that this phenom-
enon modulates the expression of genes related to angiogenic 
processes in atherosclerosis.
Additional suggestive signals of potential relevance were 
observed when both the presence/absence of CV events 
(including IHD) and subclinical atherosclerosis were tested. 
Figure 3. Interaction network formed by the encoded proteins of genes showing P values of potential relevance in our study (P < 1 × 10−4), 
according to the presence/absence of carotid plaques. The width of the gray lines indicates the reliability of each interaction. Proteins of the 
collagen biosynthetic process pathway (GO number 0032964) are highlighted in red.
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However, those signals did not reach the genome- wide level 
of significance, probably due to insufficient statistical power 
to detect risk variants with low- to- moderate effects. Biologic 
pathway enrichment and protein–protein interaction analyses 
revealed a functional enrichment of the collagen biosynthesis 
network according to the presence/absence of carotid plaques. 
This result is consistent with the fact that collagen constitutes 
the main component of the fibrous cap of the carotid plaque 
and contributes to its structural integrity and vulnerability (51). 
Indeed, a recent Metabochip analysis performed in American 
patients with RA revealed a suggestive association between 
a genetic variant in the Colα1(IV) gene (COL4A1) and carotid 
plaques (52).
Finally, our results support the implication of the previously 
reported candidate CV risk gene NFKB1 and suggest a potential 
influence of both MSRA and ZC3HC1 in the development of CV 
disease in RA. In contrast, a relevant influence of the HLA region in 
this process, though suggested previously by others (8), was not 
supported by our data.
There is evidence that current CV risk screening and man-
agement strategies underestimate the actual degree of predis-
position to CV in patients with RA. In this context, genetic mark-
ers related to the development of CV disease in patients with 
RA may be used as additional tools to identify those patients 
at high CV risk, who may definitively benefit from active therapy 
to prevent CV events. Accordingly, the results of our study may 
help in the design of efficient tools to identify RA patients who 
are more likely to develop CV disease based on their genetic 
background.
A potential major limitation of the present study is the 
lack of replication of the discovery findings in an independent 
cohort of patients with RA. In addition, the study could have 
been underpowered to detect associations with small effect 
size. Further investigations to confirm our results are needed. 
Interestingly, Karpouzas et al reported that the frequency of 
unstable, noncalcified plaques is increased among patients 
with RA (53). Unstable plaques are very dangerous since they 
are particularly susceptible to disruption. Vulnerable plaques 
are generally characterized as those having a thin inflamed 
fibrous cap over a very large lipid core. Since the conven-
tional carotid ultrasound technique performed in our study 
did not allow us to identify the presence of unstable plaques, 
we believe further investigations aimed at identifying a poten-
tial role of the genetic variant RARB rs116199914 in the risk 
of unstable plaques should be conducted.
In conclusion, through a whole- genome screening of com-
mon genetic variation, we have identified RARB rs116199914 
as the main genetic variant associated with CIMT values 
in patients with RA. This finding could potentially lead to an 
improved ability to predict and screen for this condition and 
initiate treatment to prevent life- threatening CV events in RA 
patients.
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Corrigendum
In the article by Chong et al in the September 2013 issue of Arthritis & Rheumatism (now Arthritis & Rheumatology) 
(Fibroblast Growth Factor 2 Drives Changes in Gene Expression Following Injury to Murine Cartilage In Vitro and In 
Vivo) [page 2346–2355]), there was an error in Figure 1B (lower row: Midzone): the same image appears for “Control 
(24h)” and “Control (0 mins).” This did not affect the study results or conclusions reported in the article. A corrected 
Figure 1B is shown below.
The authors regret the error.
